← Back to Search

Calcium Channel Blocker

Verapamil Dilution for Peripheral Vasospasm

Phase < 1
Recruiting
Led By Khalil Ibrahim, MD
Research Sponsored by University of Illinois at Chicago
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up approximately 30 minutes
Awards & highlights

Study Summary

This trial will compare the efficacy and safety of IA Verapamil diluted with normal saline to undiluted IA Nicardipine during a common heart procedure. Patients will be randomly assigned to one of two groups.

Eligible Conditions
  • Burning Pain
  • Peripheral Vasospasm
  • Pain

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~approximately 30 minutes
This trial's timeline: 3 weeks for screening, Varies for treatment, and approximately 30 minutes for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Pain After Intra-arterial Calcium Channel Blocker Administration
Pain Prior to Intra-arterial Calcium Channel Blocker Administration
Radial Artery Spasm

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: VerapamilActive Control1 Intervention
Intra-arterial Verapamil 5 mg (2mL) diluted with 8 mL of normal saline
Group II: NicardipinePlacebo Group1 Intervention
Intra-arterial Nicardipine 400 mcg undiluted (8mL)

Find a Location

Who is running the clinical trial?

University of Illinois at ChicagoLead Sponsor
614 Previous Clinical Trials
1,562,251 Total Patients Enrolled
Khalil Ibrahim, MDPrincipal InvestigatorUniversity of Illinois at Chicago

Media Library

Nicardipine (Calcium Channel Blocker) Clinical Trial Eligibility Overview. Trial Name: NCT05625503 — Phase < 1
Burning Pain Research Study Groups: Verapamil, Nicardipine
Burning Pain Clinical Trial 2023: Nicardipine Highlights & Side Effects. Trial Name: NCT05625503 — Phase < 1
Nicardipine (Calcium Channel Blocker) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05625503 — Phase < 1
~41 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top